e-learning
resources
Amsterdam 2011
Sunday, 25.09.2011
Airway smooth muscle cells and fibroblasts: cell biology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LSC 2011 Abstract: Potential anti-inflammatory role of the cAMP effectors Epac and PKA in COPD
A. Oldenburger, S. Roscioni, E. Jansen, M. Menzen, A. Halayko, W. Timens, H. Meurs, H. Maarsingh, M. Schmidt (Groningen, Netherlands; Winnipeg, Canada)
Source:
Annual Congress 2011 - Airway smooth muscle cells and fibroblasts: cell biology
Session:
Airway smooth muscle cells and fibroblasts: cell biology
Session type:
Thematic Poster Session
Number:
755
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Oldenburger, S. Roscioni, E. Jansen, M. Menzen, A. Halayko, W. Timens, H. Meurs, H. Maarsingh, M. Schmidt (Groningen, Netherlands; Winnipeg, Canada). LSC 2011 Abstract: Potential anti-inflammatory role of the cAMP effectors Epac and PKA in COPD. Eur Respir J 2011; 38: Suppl. 55, 755
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Decreased Wnt/β-catenin signaling in COPD: Possible involvement of Wnt antagonists
Source: Annual Congress 2012 - New mechanisms in non-neoplastic and neoplastic lung diseases
Year: 2012
Phosphoinositide 3-kinase ? inhibitor suppresses interleukin-17 expression in a murine asthma model
Source: Eur Respir J 2010; 36: 1448-1459
Year: 2010
The effect of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild to moderate asthma
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
Egr-1 regulates muc5ac expression through activator protein-1 (AP-1) in chronic airway inflammation diseases
Source: International Congress 2015 – Translational studies in airway cell biology
Year: 2015
Late Breaking Abstract - CRAC channel inhibition by RP3128 triggers potent anti-inflammatory effects in COPD or asthmatic patient-derived primary cells
Source: International Congress 2018 – New pharmacological strategies in airway diseases
Year: 2018
Maintenance of IRF1 by MAPK inhibition: A mechanism by which DUSP1 reduces glucocorticoid inhibition of CXCL10
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Year: 2016
Decreased PTEN amplifies PI3K signaling and enhances pro-inflammatory cytokine release in COPD
Source: International Congress 2016 – Studies in airway cell biology
Year: 2016
Activation of IL-32 pathway in COPD
Source: Annual Congress 2008 - Cell biology of asthma and COPD
Year: 2008
LSC 2010 Abstract: Bacterial-induced protection against asthma through a novel multi-component immunoregulatory mechanism
Source: Annual Congress 2010 - Immune modulation of airways diseases
Year: 2010
Role of the kinase-dependent functions of RIPK1 in COPD
Source: Virtual Congress 2020 – Physiological and cellular mechanisms affecting pulmonary pathologies
Year: 2020
Impaired MAP kinase-dependent modulation of transcription factor T-bet in T-lymphocytes from asthmatics - role of dexamethasone
Source: Eur Respir J 2005; 26: Suppl. 49, 233s
Year: 2005
The effect of a novel phosphoinositide 3-kinase Δ inhibitor (PI3KΔ), GSK2269557, on potential biomarkers measured from the lungs of healthy male smokers
Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases
Year: 2013
Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells
Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control
Year: 2018
Inhibition of p38 mitogen-activated protein kinase has no effect on macrophage phagocytosis of bacteria in patients with COPD
Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection
Year: 2013
Inhibition of phosphodiesterase 4B enhances glucocorticoid-dependent gene transcription in human airway epithelial cells: Implications for the treatment of COPD
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
LSC 2010 Abstract: Genetic or pharmacologic inhibition of ATX stimulates LPS-induced pulmonary inflammation
Source: Annual Congress 2010 - Acute lung injury: barrier properties and leukocyte activation
Year: 2010
LSC 2011 Abstract: Suppression of antitumor immunity as a potential link between inflammation and cancer in COPD
Source: Annual Congress 2011 - COPD: human studies
Year: 2011
NLRP3 inflammasome is activated via phosphoinositide 3-kinase δ pathway in Aspergillus fumigatus-induced allergic airway inflammation
Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions
Year: 2015
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile
Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Year: 2014
Activation of second messenger pathways in alveolar macrophages by endotoxin
Source: Eur Respir J 2002; 20: 210-222
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept